Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2026

DelveInsight's, "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Janus Kinase (JAK) Inhibitor: Understanding

Janus Kinase (JAK) Inhibitor: Overview

Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses. The family of cytokines that signal via JAKs includes many interleukins, interferons, colony stimulating factors and hormonelike cytokines (such as erythropoietin). The receptors for these cytokines signal via various combinations of four JAKs (JAK1, JAK2, JAK3 and TYK2). First-generation jakinibs, such as tofacitinib and baricitinib (and oclacitinib in dogs), block more than one JAK, and thereby can inhibit a large number of cytokines; these and other pan-jakinibs are being investigated as therapeutic agents for a wide variety of autoimmune diseases.

JAK-STAT pathways are utilised by type I and II cytokine receptors, as well as by receptors for interferons and growth factors. These receptors lack intrinsic catalytic activity and rely on JAKs for downstream responses and subsequent modulation of gene expression Janus is the Greek god of doorways, looking both outside and inside a room, and illustrates how JAKs facilitate signals from the cell surface into the cell. Each cytokine receptor is paired with a different JAK pair, usually as heterodimers.

Upon cross-linking by its cytokine, the receptor-associated JAKs transphosphorylate one another. The activated JAKs in turn phosphorylate the cytokine receptor tail. The phosphorylated receptor forms a docking site for STATs, that otherwise reside in the cytosol. These STATs are then phosphorylated by the JAKs before dissociating from the receptor and themselves forming heterodimers or homodimers. They then translocate to the nucleus where they act as transcription factors, regulating gene expression.

There are seven mammalian STATS which, like JAKs, associate with different signaling pathways.

Dysregulation of JAK catalytic activity can manifest as either a reduction or an increase in kinase activity, and is observed in pathogeneses including immunodeficiency, inflammatory diseases, hematological defects, autoimmune and myeloproliferative disorders, and susceptibility to infection. Altered Jak regulation occurs by multiple mechanisms, including: gene translocations, somatic or inherited point mutations, receptor mutations, and alterations in the activity of JAK regulators such as SOCS or phosphatases. The development of kinase inhibitors has offered new therapies for diverse clinical entities ranging from malignancy to autoimmunity. JAK inhibitors initially launched to treat a rare hematologic disorder are now progressing to be used in not only malignancies but common autoimmune disorders as well.

The linkage of these pathologies with altered JAK catalytic activity has increased interest in development of JAK-specific inhibitors to treat classical myeloproliferative disorders and cancers, or to be used as immunosuppressant. Structural biology plays an important role in rational inhibitor design, and consequently, over the last few years crystal structures for all of the enzymatically active JAK kinase domains have been determined in complex with various ATP-competitive inhibitors.

"Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Janus Kinase (JAK) Inhibitor pipeline landscape is provided which includes the disease overview and Janus Kinase (JAK) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Janus Kinase (JAK) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Janus Kinase (JAK) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Janus Kinase (JAK) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Janus Kinase (JAK) Inhibitor.

Janus Kinase (JAK) Inhibitor Emerging Drugs Chapters

This segment of the Janus Kinase (JAK) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Janus Kinase (JAK) Inhibitor Emerging Drugs

• BHV-8000: Biohaven, Ltd.

BHV-8000 is an investigational oral, brain-penetrant, dual TYK2/JAK1 inhibitor that targets the Janus kinase-STAT (JAK-STAT) signaling pathway. The drug selectively inhibits TYK2 and JAK1, while avoiding JAK2/JAK3 inhibition, with the aim of modulating inflammatory signaling involved in neuroinflammation. BHV-8000 is capable of inhibiting complementary immune pathways, including Th17-cell generation and Type I interferon signaling, and reducing inflammatory activity involving microglia, astrocytes, and infiltrating T cells. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Parkinson's disease.

• Modzatinib (ATI-2138): Aclaris Therapeutics

Modzatinib (ATI-2138) is an investigational oral, covalent dual inhibitor of interleukin-2-inducible T-cell kinase (ITK) and Janus kinase 3 (JAK3). As a JAK inhibitor, modzatinib selectively targets JAK3, which mediates signaling of common gamma-chain cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, thereby modulating lymphocyte activation and proliferation. Its additional inhibition of ITK interferes with T-cell receptor signaling, providing a dual mechanism aimed at reducing T-cell differentiation, activation, and cytokine production. Aclaris has reported high potency against both ITK and JAK3, while showing selectivity over JAK1 and JAK2. In August 2026, the US Food and Drug Administration has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Atopic dermatitis and Lichen planus.

• LNK01004: Lynk Pharmaceuticals

LNK01004 is an investigational topical soft pan-Janus kinase (JAK) inhibitor being developed for inflammatory and autoimmune dermatological diseases. The drug is designed to inhibit multiple JAK-mediated cytokine signaling pathways while maintaining low systemic exposure and skin-restricted distribution, with the aim of combining the broad activity of pan-JAK inhibition with a potentially improved systemic safety profile. LNK01004 is formulated as an ointment for topical administration and has demonstrated low measurable concentrations in blood following application. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Atopic dermatitis.

• AJ1-11095: Eli Lilly and Company

AJ1-11095 is an investigational, oral, first-in-class type II JAK2 inhibitor. AJ1-11095 is designed to bind JAK2 in its inactive conformation which is an approach intended to more completely suppress the aberrant signaling that drives myelofibrosis, in contrast to currently approved JAK2 inhibitors that bind JAK2 in its active state. AJ1-11095 demonstrated superior activity compared to ruxolitinib in preclinical models of myelofibrosis. AJ1-11095 is currently being studied in AJX-101, a global, open-label, multicenter, Phase I study in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have previously been treated with a type I JAK2 inhibitor.

• SDC-1801: Sareum Holdings

SDC-1801 is a novel, orally administered small-molecule dual TYK2/JAK1 inhibitor being developed for the treatment of autoimmune diseases, with psoriasis as the planned initial indication. The compound is designed to selectively inhibit TYK2 and JAK1 while showing greater selectivity over related JAK2 and JAK3 kinases, and has demonstrated activity in preclinical models of psoriasis and rheumatoid arthritis. SDC-1801 has completed its Phase I clinical study, in which it demonstrated a generally well-tolerated safety profile, pharmacokinetic characteristics supportive of once-daily dosing, and evidence of sustained TYK2/JAK1 target engagement.

Janus Kinase (JAK) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Janus Kinase (JAK) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Janus Kinase (JAK) Inhibitor

There are approx. 75+ key companies which are developing the therapies Janus Kinase (JAK) Inhibitor. The companies which have their Janus Kinase (JAK) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Biohaven, Ltd., and others.

• Phases

DelveInsight's report covers around 90+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Janus Kinase (JAK) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Janus Kinase (JAK) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Janus Kinase (JAK) Inhibitor drugs.

Janus Kinase (JAK) Inhibitor Report Insights

• Janus Kinase (JAK) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Janus Kinase (JAK) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Janus Kinase (JAK) Inhibitor drugs?
• How many Janus Kinase (JAK) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Janus Kinase (JAK) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Janus Kinase (JAK) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Janus Kinase (JAK) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biohaven, Ltd.
• Aclaris Therapeutics
• Lynk Pharmaceuticals
• Eli Lilly and Company
• Sareum Holdings
• Accropeutics
• Shanghai Fosun Pharmaceutical
• Prelude Therapeutics
• Incyte
• Celon Pharma
• Sundance Biosciences
• Inventis Bio
• Takeda
• Beijing InnoCare Pharma Tech Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Key Products

• BHV-8000
• Modzatinib (ATI-2138)
• LNK01004
• LNK01001
• AJ1-11095
• SDC-1802
• SDC-1801
• FXS-5626/AC-201
• PRT12396
• CPL 409116
• SUN-111
• D-2570
• TAK-279
• ICP-332 (soficitinib)
• ICP-488 (Fadeucravacitinib)
• TQH3906